Dietary clofibric acid increases intestinal fatty acid binding protein activity and apparent lipid digestibility in weanling swine.
The effects of supplementation of dietary clofibric acid (.5% wt/wt) on fatty acid binding protein (FABP) activity, apparent lipid digestibility, and serum cholesterol concentrations were evaluated in weanling pigs. Twenty-four barrows were allotted by weight and litter to a randomized complete block design with two treatments (basal vs clofibric acid) in six replicates. Nutrient digestibility measurements were made for a 2-wk period, after which the pigs were killed and tissues were collected. No differences in BW, liver, proximal small intestine, distal small intestine, and proximal and distal intestinal mucosa weights were observed. Apparent lipid digestibility was greater (P < .05) for the overall 2-wk period in clofibric acid-supplemented pigs (81.5 vs 76.6%). This paralleled the increased FABP activity in the distal small intestine (P < .001) of clofibric acid-supplemented pigs. Proximal intestine and liver FABP activities were unaffected by dietary treatment. Serum cholesterol concentrations were markedly lowered by clofibric acid supplementation. During wk 1, pigs fed the basal diet had twofold greater (P < .01) serum cholesterol concentrations, whereas during wk 2, basal-fed pigs had fourfold greater (P < .01) serum cholesterol concentrations (81.5 vs 18.3 mg/dL). These results suggest that elevated intestinal FABP activities may augment fatty acid absorption from the gastrointestinal tract.
Reinhart
G A
GA
Department of Animal Science, Ohio State University, Columbus 43210.
Mahan
D C
DC
Lepine
A J
AJ
Simmen
F A
FA
Moore
B E
BE
D000821:Animal Feed; D000818:Animals; D002352:Carrier Proteins / Q000378:metabolism*; D002784:Cholesterol / Q000097:blood; D002995:Clofibric Acid / Q000494:pharmacology*; D004063:Digestion / Q000187:drug effects*; D050556:Fatty Acid-Binding Proteins; D005227:Fatty Acids / Q000378:metabolism; D005527:Food, Fortified; D007421:Intestine, Small / Q000187:drug effects / Q000378:metabolism; D050356:Lipid Metabolism; D008099:Liver / Q000187:drug effects; D008297:Male; D009363:Neoplasm Proteins; D011897:Random Allocation; D013552:Swine / Q000254:growth & development / Q000502:physiology*; D014886:Weaning
D002352:Carrier Proteins; D050556:Fatty Acid-Binding Proteins; D005227:Fatty Acids; D009363:Neoplasm Proteins; D002995:Clofibric Acid; D002784:Cholesterol